AU6613996A - Heterocyclic compounds and pharmaceutical compositions containing them - Google Patents

Heterocyclic compounds and pharmaceutical compositions containing them

Info

Publication number
AU6613996A
AU6613996A AU66139/96A AU6613996A AU6613996A AU 6613996 A AU6613996 A AU 6613996A AU 66139/96 A AU66139/96 A AU 66139/96A AU 6613996 A AU6613996 A AU 6613996A AU 6613996 A AU6613996 A AU 6613996A
Authority
AU
Australia
Prior art keywords
pharmaceutical compositions
compositions containing
heterocyclic compounds
heterocyclic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66139/96A
Other languages
English (en)
Inventor
Paul Barraclough
Malcolm Clive Carter
George Stuart Cockerill
Karl Witold Franzmann
Alan Thomas Hudson
Stephen Karl Mckeown
Martin John Page
Sadie Vile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU6613996A publication Critical patent/AU6613996A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU66139/96A 1995-07-13 1996-07-11 Heterocyclic compounds and pharmaceutical compositions containing them Abandoned AU6613996A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9514265 1995-07-13
GBGB9514265.9A GB9514265D0 (en) 1995-07-13 1995-07-13 Hetrocyclic compounds
PCT/EP1996/003026 WO1997003069A1 (en) 1995-07-13 1996-07-11 Heterocyclic compounds and pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
AU6613996A true AU6613996A (en) 1997-02-10

Family

ID=10777551

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66139/96A Abandoned AU6613996A (en) 1995-07-13 1996-07-11 Heterocyclic compounds and pharmaceutical compositions containing them

Country Status (7)

Country Link
EP (1) EP0843671A1 (ja)
JP (1) JPH11508906A (ja)
AU (1) AU6613996A (ja)
GB (1) GB9514265D0 (ja)
HR (1) HRP960316A2 (ja)
WO (1) WO1997003069A1 (ja)
ZA (1) ZA965935B (ja)

Families Citing this family (189)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW321649B (ja) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
US5932574A (en) * 1995-04-27 1999-08-03 Zeneca Limited Quinazoline derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
HUP9901155A3 (en) 1996-02-13 2003-04-28 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
DK0885198T3 (da) 1996-03-05 2002-03-25 Astrazeneca Ab 4-Anilinoquinazolinderivater
CA2249446C (en) 1996-04-12 2008-06-17 Warner-Lambert Company Irreversible inhibitors of tyrosine kinases
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
ID19609A (id) 1996-07-13 1998-07-23 Glaxo Group Ltd Senyawa-senyawa heterosiklik
EP0927164A1 (en) 1996-09-10 1999-07-07 PHARMACIA & UPJOHN COMPANY 8-hydroxy-7-substituted quinolines as anti-viral agents
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
EP1007042A4 (en) * 1997-06-13 2001-07-04 Sugen Inc NEW HETEROCYCLIC COMPOUNDS FOR MODULATING THE PROTEIN-TYROSIN-ENZYME-RELATED CELLULAR SIGNAL TRANSDUCTION
DE69838172T2 (de) 1997-08-22 2008-04-10 Astrazeneca Ab Oxindolylchinazolinderivate als angiogenesehemmer
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
JP2002523403A (ja) * 1998-08-21 2002-07-30 パーカー ヒューズ インスティテュート キナゾリン誘導体
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
JP2002527436A (ja) * 1998-10-08 2002-08-27 アストラゼネカ アクチボラグ キナゾリン誘導体
GB9822450D0 (en) * 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
ATE556713T1 (de) 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2000043383A1 (en) * 1999-01-20 2000-07-27 Smithkline Beecham P.L.C. Piperidinylquinolines as protein tyrosine kinase inhibitors
EE05345B1 (et) 1999-02-10 2010-10-15 Astrazeneca Ab Kinasoliini derivaadid angiogeneesi inhibiitoritena
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
TWI262914B (en) * 1999-07-02 2006-10-01 Agouron Pharma Compounds and pharmaceutical compositions for inhibiting protein kinases
KR20020029419A (ko) * 1999-07-07 2002-04-18 다비드 에 질레스 퀴나졸린 유도체
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
DE60037020T2 (de) 1999-07-09 2008-08-21 Glaxo Group Ltd., Greenford Anilinochinazoline als protein-tyrosin-kinasehemmer
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
MXPA02002898A (es) 1999-09-17 2003-10-14 Abbott Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US7071199B1 (en) 1999-09-17 2006-07-04 Abbott Gmbh & Cco. Kg Kinase inhibitors as therapeutic agents
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
WO2001066099A2 (en) 2000-03-06 2001-09-13 Astrazeneca Ab Use of quinazoline derivatives as angiogenesis inhibitors
AU2001246850A1 (en) * 2000-04-06 2001-10-23 Kyowa Hakko Kogyo Co. Ltd. Diagnostics and remedies for rheumatoid arthritis
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU7425801A (en) 2000-06-24 2002-01-08 Astrazeneca Ab Guanidine derivatives of quinazoline and quinoline for use in the treatment of autoimmune diseases
ATE394102T1 (de) * 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
CZ2003243A3 (cs) 2000-07-26 2003-09-17 Smithkline Beecham P. L. C. Aminopiperidinové chinoliny a jejich azaisosterické analogy s antibakteriální aktivitou
NZ523358A (en) 2000-08-09 2004-09-24 Astrazeneca Ab Quinoline derivatives having VEGF inhibiting activity
KR20080027400A (ko) 2000-08-21 2008-03-26 아스트라제네카 아베 퀴나졸린 유도체
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
AU9327501A (en) * 2000-09-11 2002-03-26 Chiron Corp Quinolinone derivatives
EP1318984A1 (en) 2000-09-20 2003-06-18 MERCK PATENT GmbH 4-amino-quinazolines
US6849625B2 (en) 2000-10-13 2005-02-01 Astrazeneca Ab Quinazoline derivatives with anti-tumour activity
ATE399766T1 (de) 2000-10-20 2008-07-15 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische heterozyklen
JP2004512335A (ja) * 2000-10-25 2004-04-22 アストラゼネカ　アクチボラグ キナゾリン誘導体
DE60144284D1 (de) 2000-11-01 2011-05-05 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
AU2001295791A1 (en) 2000-11-02 2002-05-15 Astrazeneca Ab 4-substituted quinolines as antitumor agents
JP2004514718A (ja) 2000-11-02 2004-05-20 アストラゼネカ　アクチボラグ 抗癌剤としての置換キノリン類
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
TWI336328B (en) * 2001-03-23 2011-01-21 Bayer Healthcare Llc Rho-kinase inhibitors
ATE325795T1 (de) * 2001-03-23 2006-06-15 Bayer Corp Rho-kinase inhibitoren
CN1300116C (zh) * 2001-04-16 2007-02-14 卫材株式会社 1h－吲唑化合物
ES2312557T3 (es) 2001-04-19 2009-03-01 Astrazeneca Ab Derivados de quinazolina.
GB0112834D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
KR100810468B1 (ko) * 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
CA2465068A1 (en) * 2001-11-03 2003-05-15 Astrazeneca Ab Quinazoline derivatives as antitumor agents
WO2003055866A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
IL162541A0 (en) 2001-12-24 2005-11-20 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
US20040014755A1 (en) 2002-01-10 2004-01-22 Dhanapalan Nagarathnam Rho-kinase inhibitors
MXPA04007191A (es) 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
JP4423043B2 (ja) 2002-01-23 2010-03-03 バイエル ファーマセチカル コーポレーション Ｒｈｏ−キナーゼ阻害剤
EP1470125A1 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine derivatives
EP1470131A2 (en) 2002-01-29 2004-10-27 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
CA2473572C (en) * 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
ATE429230T1 (de) 2002-07-09 2009-05-15 Astrazeneca Ab Chinazoline derivative und ihre anwendung in der krebsbehandlung
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
AU2003250701A1 (en) 2002-07-31 2004-02-16 Wayne R. Danter Protein tyrosine kinase inhibitors
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP1551824B1 (en) 2002-10-09 2007-12-12 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP1581217A4 (en) * 2002-11-01 2007-07-11 Merck & Co Inc CARBONYLAMINO-BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF THE ANDROGEN RECEPTOR
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
CN100354278C (zh) * 2002-11-04 2007-12-12 阿斯利康(瑞典)有限公司 作为src酪氨酸激酶抑制剂的喹唑啉衍生物
AU2003278383B2 (en) 2002-11-04 2007-06-14 Astrazeneca Ab Quinazoline derivatives as Src tyrosine kinase inhibitors
EP1565187A4 (en) 2002-11-13 2010-02-17 Novartis Vaccines & Diagnostic CANCER TREATMENT METHODS AND RELATED METHODS
DE10260730A1 (de) 2002-12-23 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte stickstoffhaltige Heterobicyclen, deren Herstellung und deren Verwendung als Arzneimittel
US7429597B2 (en) 2002-12-23 2008-09-30 Boehringer Ingelheim Pharma Gmbh & Co., Kg Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
PT1578755E (pt) 2002-12-24 2007-10-19 Astrazeneca Ab Derivados de fosfonooxiquinazolina e sua utilização farmacêutica
GB0307333D0 (en) * 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309009D0 (en) * 2003-04-22 2003-05-28 Astrazeneca Ab Quinazoline derivatives
GB0309850D0 (en) 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
US20070020704A1 (en) 2003-05-20 2007-01-25 Scott Wilhelm Diaryl ureas with kinase inhibiting activity
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
PT1667991E (pt) 2003-09-16 2008-07-14 Astrazeneca Ab Derivados de quinazolina como inibidores da tirosina cinase
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
EP1699780A1 (en) 2003-12-23 2006-09-13 Pfizer, Inc. Novel quinoline derivatives
GB0330043D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
GB0330042D0 (en) 2003-12-24 2004-01-28 Pharmacia Italia Spa Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
WO2005070891A2 (en) 2004-01-23 2005-08-04 Amgen Inc Compounds and methods of use
CA2553433A1 (en) * 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
BRPI0507891A (pt) 2004-02-20 2007-07-24 Chiron Corp modulação dos processos inflamatório e metastático
ME01267B (me) 2004-05-06 2013-06-20 Warner Lambert Co 4-fenilaminokinazolin-6-ilamidi
BRPI0511741A (pt) * 2004-06-04 2008-01-02 Astrazeneca Ab derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
AU2005251735A1 (en) 2004-06-04 2005-12-22 Amphora Discovery Corporation Quinoline- and isoquinoline-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
ES2450566T3 (es) 2004-11-30 2014-03-25 Amgen Inc. Análogos de quinazolina y quinolinas y su uso como medicamentos para tratar el cáncer
JP4881875B2 (ja) 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ 抗腫瘍剤としてのピラゾロピリミジン化合物
US7358256B2 (en) 2005-03-28 2008-04-15 Bristol-Myers Squibb Company ATP competitive kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
WO2006124413A2 (en) 2005-05-13 2006-11-23 Novartis Ag Methods for treating drug resistant cancer
RU2437878C2 (ru) 2005-05-17 2011-12-27 Новартис Аг Способы получения гетероциклических соединений
CN102070614B (zh) 2005-05-23 2014-01-15 诺华股份有限公司 4-氨基-5-氟-3-[6-(4-甲基哌嗪-1-基)-1h-苯并咪唑-2-基]-1h-喹啉-2-酮乳酸盐的结晶和其它形式
CN101263125A (zh) * 2005-07-15 2008-09-10 先灵公司 用于癌症治疗的喹唑啉衍生物
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
ES2354457T3 (es) 2005-09-20 2011-03-15 Astrazeneca Ab Compuestos de 4-(1h-indazol-5-il-amino)-quinazolina como inhibidores del receptor erbb de la tirosina quinasa para el tratamiento del cáncer.
BRPI0708034A2 (pt) 2006-02-10 2011-05-17 Transtech Pharma Inc derivados benzazol, composições e métodos de uso como inibidores aurora quinase
UY30183A1 (es) 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
JP5368096B2 (ja) 2006-08-28 2013-12-18 エーザイ・アール・アンド・ディー・マネジメント株式会社 未分化型胃癌に対する抗腫瘍剤
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
US8138191B2 (en) 2007-01-11 2012-03-20 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
EP2119707B1 (en) 2007-01-29 2015-01-14 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
CA2677336A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof
WO2009037343A1 (en) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
EP2220078B1 (en) 2007-10-29 2013-05-22 Amgen, Inc Benzomorpholine derivatives and methods of use
UA101168C2 (ru) 2007-10-29 2013-03-11 Натко Фарма Лимитед 4-(тетразол-5-ил)хиназолиновые производные как противораковые средства
CN101848895B (zh) 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2225226B1 (en) 2007-12-26 2016-08-17 Critical Outcome Technologies, Inc. Compounds and their use in a method for treatment of cancer
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
CA2723989C (en) 2008-05-13 2017-04-25 Astrazeneca Ab Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
WO2010015522A1 (de) 2008-08-08 2010-02-11 Boehringer Ingelheim International Gmbh Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
DK3575288T3 (da) 2009-09-03 2021-12-20 Bristol Myers Squibb Co Quinazoliner som kaliumionkanalinhibitorer
CA2999435A1 (en) 2010-04-01 2011-10-06 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
KR101945061B1 (ko) * 2010-07-29 2019-02-01 메르크 파텐트 게엠베하 시클릭 아민 아자헤테로시클릭 카르복사미드
SG193291A1 (en) 2011-03-04 2013-10-30 Newgen Therapeutics Inc Alkyne substituted quinazoline compound and methods of use
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
CN102942561A (zh) * 2012-11-06 2013-02-27 深圳海王药业有限公司 4-氨基喹唑啉杂环化合物及其用途
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014127214A1 (en) 2013-02-15 2014-08-21 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
CN105102450B (zh) 2013-04-04 2018-03-09 詹森药业有限公司 作为PERK抑制剂的N‑(2，3‑二氢‑1H‑吡咯并[2，3‑b]吡啶‑5‑基)‑4‑喹唑啉胺和N‑(2，3‑二氢‑1H‑吲哚‑5‑基)‑4‑喹唑啉胺衍生物
ES2687968T3 (es) 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
AR096654A1 (es) * 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
CA2922279C (en) 2013-09-16 2022-08-16 Astrazeneca Ab Therapeutic polymeric nanoparticles and methods of making and using same
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2015150995A1 (en) * 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
KR20170122734A (ko) 2015-02-25 2017-11-06 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CN104725364B (zh) * 2015-03-12 2017-09-15 江苏省中国科学院植物研究所 6,7‑二甲氧基‑喹唑啉‑4‑胺衍生物、其制备方法及医药用途
KR20180018695A (ko) 2015-06-16 2018-02-21 가부시키가이샤 프리즘 파마 항암제
BR112018006873A2 (pt) 2015-10-05 2018-11-06 The Trustees Of Columbia University In The City Of New York ativadores do fluxo autofágico e fosfolipase d e depuração de agregados de proteína incluindo tau e tratamento de proteinopatias
CN106045980B (zh) * 2016-06-03 2017-11-03 江苏开放大学 一种喹唑啉衍生物及其制备方法
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324251A1 (en) 2016-09-08 2019-03-21 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
JP7128204B2 (ja) 2017-04-27 2022-08-30 アストラゼネカ・アクチエボラーグ Ｃ５－アニリノキナゾリン化合物及び癌の処置におけるそれらの使用
JP7117323B2 (ja) * 2017-04-27 2022-08-12 アストラゼネカ・アクチエボラーグ フェノキシキナゾリン化合物及び癌の処置におけるそれらの使用
AU2018341454B2 (en) * 2017-09-26 2023-09-28 The Regents Of The University Of California Compositions and methods for treating cancer
FR3080620B1 (fr) * 2018-04-27 2021-11-12 Univ Paris Sud Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
TW321649B (ja) * 1994-11-12 1997-12-01 Zeneca Ltd

Also Published As

Publication number Publication date
WO1997003069A1 (en) 1997-01-30
HRP960316A2 (en) 1998-02-28
JPH11508906A (ja) 1999-08-03
GB9514265D0 (en) 1995-09-13
ZA965935B (en) 1998-02-12
EP0843671A1 (en) 1998-05-27

Similar Documents

Publication Publication Date Title
AU6613996A (en) Heterocyclic compounds and pharmaceutical compositions containing them
IL116957A0 (en) Substituted heterocyclic compounds their preparation and pharmaceutical compositions containing them
IL116851A (en) 3-arylidene-2-oxindole derivatives and pharmaceutical compositions containing them
AU6232096A (en) Aromatic compounds and pharmaceutical compositions containing them
IL119078A (en) Substituted benzylaminopiperidine compounds and pharmaceutical compositions comprising them
IL116455A0 (en) Imidazole compounds and pharmaceutical compositions containing them
AU6418596A (en) Compounds and pharmaceutical compositions containing them
HUP9802999A3 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
IL116917A0 (en) Piperidine derivatives and pharmaceutical compositions containing the same
AU6216296A (en) Pharmaceutical compositions
HUP0000474A3 (en) Arylethenesulfonamide derivatives and drug composition containing the same
AU6232196A (en) Aromatic compounds and pharmaceutical compositions containing them
AU7590096A (en) Drug composition
HUP9802290A3 (en) Pyrrole derivatives and pharmaceutical compositions containing them
AU5856898A (en) Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them
IL117620A0 (en) Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
AU683787B2 (en) Aromatic heterocyclic compounds, pharmaceutical and cosmetic compositions containing them and uses thereof
IL118221A0 (en) Substituted cephalosporins and pharmaceutical compositions containing them
AU5100393A (en) Diindolo compounds and pharmaceutical compositions containing them
AU5155096A (en) Pharmaceutical composition
AU7904998A (en) Pharmaceutical composition containing peptichemio
AU6835996A (en) Pyridinium derivatives and pharmaceutical compositions containing them
AU5274096A (en) Pharmaceutical compositions
AU5326298A (en) Pharmaceutical compositions containing N-sulphonylindoline derivatives
AU1172097A (en) Pharmaceutical composition containing trehalose